MEDIPOST receives US Patent for ‘PNEUMOSTEM’ for Treating Lung Disease

MEDIPOST Obtains Patent in US for its Alzheimer’s Disease Treatment Drug

MEDIPOST Obtains Patent in US for its Arthritis Treatment Technique

MEDIPOST Completes Phase 1 and 2 Clinical Trials with its Lung Disease Treatment Drug ‘PNEUMOSTEM’ in US

MEDIPOST Obtains Patent in China for Its Brain Disease Treatment Technology that Uses Stem Cells

MEDIPOST Signs MOU with Canadian Public-Private Consortium Funded by the Government of Canada

MEDIPOST Obtains Patent in US for its Next-Generation Stem Cell Culturing Technology

MEDIPOST’s Stem Cell Drug ‘CARTISTEM’ Hits 5,000 Sales Mark

Chinese Securities Company Praises MEDIPOST as a “Company with Most Profitable Stem Cell Drug”

MEDIPOST Begins Sales of its Stem Cell Drug, ‘CARTISTEM’

MEDIPOST Obtains Patent in UK for its Alzheimer’s Disease Treatment Technique that Uses Stem Cells

MEDIPOST Obtains Patent for its High-Efficient Technology for Culturing Stem Cells